赢8娱乐糖果配对游戏-官方网站[welcome]


+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Once daily treatment with the nonsteroidal antiandrogen casodex for advanced prostate cancer



Once daily treatment with the nonsteroidal antiandrogen casodex for advanced prostate cancer



Journal of Urology 143(4 Suppl.): 308A




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 032638870

Download citation: RISBibTeXText


Related references

Efficacy and safety of the nonsteroidal antiandrogen casodex in the treatment of advanced prostate cancer. Journal of Urology 141(4 Part 2): 346A, 1989

Clinical trials with the nonsteroidal antiandrogen casodex in the treatment of advanced prostate cancer. Cancer Investigation 9(3): 384, 1991

Casodex 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex Study Group. European Urology 33(1): 39-53, 1998

Antagonist/agonist balance of the nonsteroidal antiandrogen bicalutamide (Casodex) in a new prostate cancer model. Urologia Internationalis 65(2): 73-79, 2000

Antagonist/Agonist Balance of the Nonsteroidal Antiandrogen Bicalutamide (Casodex) in a New Prostate Cancer Model. Urologia Internationalis 65(2): 73-79, 2000

Casodex Tm 10–200 mg Daily, Used as Monotherapy for the Treatment of Patients with Advanced Prostate Cancer. European Urology 33(1): 39-53, 1998

Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro. International Journal of Cancer 115(4): 630-640, 2005

Casodex (bicalutamide): overview of a new antiandrogen developed for the treatment of prostate cancer. European Urology 31(Suppl. 2): 30-39, 1997

Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with the nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response to maximal androgen blockade. European Urology 31(2): 216-219, 1997

Feasibility study for the treatment of metastatic prostate cancer with the radioactive antiandrogen I-125-bicalutamide (=I-125-casodex). International Journal of Radiation Oncology*biology*physics 48(3-Supp-S1): 316-0, 2000

Phase I study of bicalutamide (Casodex), a nonsteroidal antiandrogen in patients with prostatic cancer. Hinyokika Kiyo. Acta Urologica Japonica 42(2): 143-153, 1996

PSA response to secondary androgen deprivation following failed treatment of metastatic prostate cancer with the antiandrogen casodex. Urologic Oncology 1(2): 64-66, 1995

Pathological and morphometric assessment of testicular parameters in patients with metastatic prostate cancer following treatment with either the antiandrogen Casodex (ZM176334) or bilateral orchidectomy. Urological Research 22(3): 191-195, 1994

Casodex ici 176334 a new steroidal antiandrogen in prostate cancer. Proceedings of the American Association for Cancer Research Annual Meeting 30: 311, 1989

Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. Journal of Urology 180(3): 921-927, 2008





赢8娱乐糖果配对游戏